Showing results (1961-1970 of 2,138) with videos related to

Sort By:
Pageof 214
Cell Stem Cell|February 23, 2021
Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative NeoplasmsDebra Van Egeren, Javier Escabi, Maximilian Nguyen, et al.
Blood|December 24, 2013
AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemiaErika K Keeton, Kristen McEachern, Keith S Dillman, et al.
The Journal of Experimental Medicine|June 22, 2016
Targeting MTHFD2 in acute myeloid leukemiaYana Pikman, Alexandre Puissant, Gabriela Alexe, et al.
JAMA Psychiatry|February 3, 2021
Trends in US Emergency Department Visits for Mental Health, Overdose, and Violence Outcomes Before and During the COVID-19 PandemicKristin M Holland, Christopher Jones, Alana M Vivolo-Kantor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patientsGuido Marcucci, Kati S Maharry, Klaus H Metzeler, et al.
Cell|March 5, 2019
Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and ImmunityPeter van Galen, Volker Hovestadt, Marc H Wadsworth Ii, et al.
Blood|September 26, 2007
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qAzra Raza, James A Reeves, Eric J Feldman, et al.
Cancer Cell|October 6, 2009
Proteomic and genetic approaches identify Syk as an AML targetCynthia K Hahn, Jacob E Berchuck, Kenneth N Ross, et al.
The Journal of Clinical Investigation|February 14, 2012
The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemiaVersha Banerji, Stacey M Frumm, Kenneth N Ross, et al.
Blood Advances|January 26, 2022
Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapyJurjen Versluis, Manu Pandey, Yael Flamand, et al.
Pageof 214